哮喘联盟

   摘要
   前言：目前市场上有效的止咳药较少。咳嗽的发生与不同迷走神经分支的共同传入相关。被广泛接受的观点认为咳嗽反射敏感性的慢性增强与炎症性超敏反应相关，例如由胃食道反流症引起。但是，越来越多的证据证实喉部迷走神经分支感觉障碍也是一个重要的机制。神经调节性药物被用于有效治疗慢性疼痛及神经病变性疾病，并可能在难治性慢性咳嗽（CC）的治疗中得到应用。
   研究范围：我们对目前关于加巴喷丁在治疗慢性咳嗽有效性及安全性方面的证据进行评估。在pubmed数据库中搜索在过去10年中发表的语言为英语，并与咳嗽、感觉神经病以及加巴喷丁相关的随机对照试验、病例报告和综述。
   专家意见：加巴喷丁能有效治疗慢性咳嗽以及其它感觉神经病变性疾病，且耐受性良好。但是关于加巴喷丁治疗咳嗽的有效性及安全性的临床试验较少，需要进行深入研究。过量使用加巴喷丁无或仅有极小毒性反应。
 

（刘国梁 审校）
Expert Opin Pharmacother. 2015 Jan;16(1):135-45. doi: 10.1517/14656566.2015.981524. Epub 2014 Nov 7.


 

A review on the efficacy and safety of gabapentin in the treatment of chronic cough.
 

Ryan NM1.
 

Abstract
INTRODUCTION: Effective antitussives available to control cough are limited. Consolidation among different afferent branches of the vagus nerve is needed to bring about cough. A general, widely accepted view is that the chronic increase in the sensitivity of the cough reflex is associated with inflammatory hypersensitivity such as from gastro-esophageal reflux disease. There is increasing evidence that an important mechanism is a sensory disorder of the laryngeal branches of the vagus nerve. Neuromodulating drugs are effectively used in the treatment of chronic pain and neuropathic disorders and may have a role in the treatment of refractory chronic cough (CC).
AREAS COVERED: Current evidence on the efficacy and safety of gabapentin in the treatment of CC is reviewed. Relevant randomized controlled trials, case reports and reviews were identified through a PubMed search of English-language literature referring to cough, sensory neuropathy and gabapentin over the last 10 years.
EXPERT OPINION: Gabapentin appears to be effective and well tolerated in the treatment of CC and in other sensory neuropathic disorders. Relevant clinical trials investigating its efficacy and safety profile in the treatment of cough are limited and further studies are needed. Gabapentin has been shown to cause minimal to no toxicity in overdose.
 

Expert Opin Pharmacother. 2015 Jan;16(1):135-45. doi: 10.1517/14656566.2015.981524. Epub 2014 Nov 7.